Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2093-2102

  Lam, Sze Kwan ^a   Mak, Judith Choi W O ^a   Zheng, Chun Yan ^a   Li, Yuan Yuan ^a   Kwong, Yok Lam ^a   Ho, James Chung Man ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Arsenic trioxide; Lung adenocarcinoma; Thymidylate synthase; Xenograft

Indexed keywords

ARSENIC TRIOXIDE; MESSENGER RNA; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY ASSAY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA CELL LINE; ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NUDE MOUSE; ADENOCARCINOMA; ANIMAL; APOPTOSIS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MICE; MICE, NUDE; OXIDES; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899554174     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2364     Document Type: Article

References (44)

1. Rahman L, Voeller D, Rahman M, et al: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004.
2. Biason P, Visentin M, Talamini R, et al: Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy. Pharmacogenomics 13: 1609-1619, 2012.
3. Bolocan A, Ion D, Ciocan DN and Paduraru DN: Prognostic and predictive factors in colorectal cancer. Chirurgia (Bucur) 107: 555-563, 2012.
4. Igawa S, Ryuge S, Wada M, et al: Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Chemotherapy 58: 313-320, 2012.
5. Ruiz-Tovar J, Fernandez-Contreras ME, Martin-Perez E and Gamallo C: Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer. Tumori 98: 364-369, 2012.
6. Tamatani T, Ferdous T, Takamaru N, et al: Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells. Int J Oncol 41: 1148-1156, 2012.
7. Yang Z, Liu HX and Zhang XF: 2R of thymidylate synthase 5'-untranslated enhanced region contributes to gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev 13: 1923-1927, 2012.
8. Subbarayan PR, Lee K and Ardalan B: Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 in vitro re-sensitizing cells to 5-FU. Anticancer Res 30: 1157-1162, 2010.
9. Rangwala F, Williams KP, Smith GR, et al: Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer 12: 402, 2012.
10. Arocho A, Chen B, Ladanyi M and Pan Q: Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn Mol Pathol 15: 56-61, 2006.
11. Pressacco J, Mitrovski B, Erlichman C and Hedley DW: Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 55: 1505-1508, 1995.
12. Kousparou CA, Yiacoumi E, Deonarain MP and Epenetos AA: Generation of a selectively cytotoxic fusion protein against p53 mutated cancers. BMC Cancer 12: 338, 2012.
13. Ardalan B, Subbarayan PR, Ramos Y, et al: A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res 16: 3019-3027, 2010.
14. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8: 3658-3668, 2002.
15. Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
16. Pao W and Hutchinson KE: Chipping away at the lung cancer genome. Nat Med 18: 349-351, 2012.
17. Au WY: A biography of arsenic and medicine in Hong Kong and China. Hong Kong Med J 17: 507-513, 2011.
18. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860, 2001.
19. Gore SD, Gojo I, Sekeres MA, et al: Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28: 1047-1053, 2010.
20. Cai X, Shen YL, Zhu Q, et al: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14: 262-270, 2000.
21. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111, 1999.
22. Mahieux R, Pise-Masison C, Gessain A, et al: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98: 3762-3769, 2001.
23. Park WH, Seol JG, Kim ES, et al: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60: 3065-3071, 2000.
24. Shim MJ, Kim HJ, Yang SJ, Lee IS, Choi HI and Kim T: Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. J Biochem Mol Biol 35: 377-383, 2002.
25. Wang ZG, Rivi R, Delva L, et al: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92: 1497-1504, 1998.
26. Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al: Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547-555, 2008.
27. Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240-243, 2010.
28. Han B, Zhou G, Zhang Q, et al: Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol 4: 335-342, 2004.
29. Cheng Y, Chang LW and Tsou TC: Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol 80: 310-318, 2006.
30. Jin HO, Yoon SI, Seo SK, et al: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 72: 1228-1236, 2006.
31. Kim HR, Kim EJ, Yang SH, et al: Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int J Oncol 28: 1401-1408, 2006.
32. De Sousa Abreu R, Penalva LO, Marcotte EM and Vogel C: Global signatures of protein and mRNA expression levels. Mol Biosyst 5: 1512-1526, 2009.
33. Belvedere O, Puglisi F, Di Loreto C, et al: Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann Oncol 15: 55-58, 2004.
34. Phan J, Steadman DJ, Koli S, et al: Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors. J Biol Chem 276: 14170-14177, 2001.
35. Salo-Ahen OM and Wade RC: The active-inactive transition of human thymidylate synthase: targeted molecular dynamics simulations. Proteins 79: 2886-2899, 2011.
36. Takezawa K, Okamoto I, Tsukioka S, et al: Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br J Cancer 103: 354-361, 2010.
37. Melo SP, Yoshida A and Berger FG: Functional dissection of the N-terminal degron of human thymidylate synthase. Biochem J 432: 217-226, 2010.
38. Jing Y, Wang L, Xia L, et al: Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97: 264-269, 2001.
39. Kim J, Lee JJ, Gardner D and Beachy PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 107: 13432-13437, 2010.
40. Kinjo K, Kizaki M, Muto A, et al: Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 14: 431-438, 2000.
41. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al: Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189: 1043-1052, 1999.
42. Li Y, Sun X, Wang L, Zhou Z and Kang YJ: Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc Toxicol 2: 63-73, 2002.
43. Au WY, Kumana CR, Kou M, et al: Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 102: 407-408, 2003.
44. Siu CW, Au WY, Yung C, et al: Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 108: 103-106, 2006.